Sg3 Management, LLC Nektar Therapeutics Call Options Transaction History

Sg3 Management, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $7,040 - $34,650	-11,000 Closed	0 $0
Q3 2022 May 15, 2023	BUY	$3.04 - $5.14 $33,440 - $56,540	11,000 New	11,000 $35,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $317,984 - $537,644	-104,600 Reduced 90.48%	11,000 $35,000
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $670,455 - $1.3 Million	-211,500 Reduced 64.66%	115,600 $439,000
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $1.27 Million - $4.2 Million	306,100 Added 1457.62%	327,100 $1.76 Million

Q4 2021 Feb 15, 2022	BUY	$10.83 - $18.41 $21,660 - $36,820	2,000 Added 10.53%	21,000 $284,000
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $248,330 - $357,960	19,000 New	19,000 $341,000
Q2 2021 Aug 16, 2021	SELL	$16.52 - $20.4 $1.07 Million - $1.33 Million	-65,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $455,399 - $700,150	27,500 Added 73.33%	65,000 $1.3 Million
Q4 2020 Feb 16, 2021	BUY	$15.77 - $19.03 $118,275 - $142,725	7,500 Added 25.0%	37,500 $638,000
Q3 2020 Nov 13, 2020	BUY	$16.59 - $24.79 $497,700 - $743,700	30,000 New	30,000 $498,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.